aXichem AB Logo

aXichem AB

AXIC-A.ST

(1.0)
Stock Price

1,48 SEK

-59.2% ROA

-28.55% ROE

-2.9x PER

Market Cap.

51.566.093,00 SEK

7.69% DER

0% Yield

-230.22% NPM

aXichem AB Stock Analysis

aXichem AB Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

aXichem AB Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (17%), which means it has a small amount of debt compared to the ownership it holds

2 Assets Growth

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

3 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

4 ROE

The stock's ROE indicates a negative return (-39.89%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-54.97%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 PBV

The stock's elevated P/BV ratio (4.2x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

7 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (-3), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

aXichem AB Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

aXichem AB Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

aXichem AB Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

aXichem AB Revenue
Year Revenue Growth
2008 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 376.000 100%
2015 0 0%
2016 0 0%
2017 0 0%
2018 344.000 100%
2019 343.000 -0.29%
2020 1.227.000 72.05%
2021 4.362.000 71.87%
2022 5.007.000 12.88%
2023 1.148.000 -336.15%
2023 1.809.000 36.54%
2024 23.468.000 92.29%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

aXichem AB Research and Development Expenses
Year Research and Development Expenses Growth
2008 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 336.000 100%
2019 514.000 34.63%
2020 736.000 30.16%
2021 910.000 19.12%
2022 1.403.000 35.14%
2023 0 0%
2023 1.619.000 100%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

aXichem AB General and Administrative Expenses
Year General and Administrative Expenses Growth
2008 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 3.270.732 100%
2013 3.184.001 -2.72%
2014 4.328.000 26.43%
2015 5.057.000 14.42%
2016 4.067.000 -24.34%
2017 5.275.000 22.9%
2018 5.667.000 6.92%
2019 6.254.000 9.39%
2020 6.036.000 -3.61%
2021 6.674.000 9.56%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

aXichem AB EBITDA
Year EBITDA Growth
2008 -622.097
2009 -1.419.237 56.17%
2010 -1.828.099 22.37%
2011 -2.091.658 12.6%
2012 -3.227.467 35.19%
2013 -3.320.576 2.8%
2014 -5.515.000 39.79%
2015 -7.330.000 24.76%
2016 -5.926.000 -23.69%
2017 -7.180.000 17.47%
2018 -8.395.000 14.47%
2019 -10.575.000 20.61%
2020 -11.276.000 6.22%
2021 -12.582.000 10.38%
2022 -11.034.000 -14.03%
2023 -11.300.000 2.35%
2023 -14.126.000 20.01%
2024 828.000 1806.04%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

aXichem AB Gross Profit
Year Gross Profit Growth
2008 0
2009 0 0%
2010 0 0%
2011 -40.000 100%
2012 -28.474 -40.48%
2013 -40.338 29.41%
2014 236.000 117.09%
2015 0 0%
2016 0 0%
2017 0 0%
2018 130.000 100%
2019 40.000 -225%
2020 596.000 93.29%
2021 909.000 34.43%
2022 3.818.000 76.19%
2023 984.000 -288.01%
2023 -17.960.000 105.48%
2024 -3.380.000 -431.36%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

aXichem AB Net Profit
Year Net Profit Growth
2008 -1.048.343
2009 -1.714.510 38.85%
2010 -2.373.899 27.78%
2011 -2.357.067 -0.71%
2012 -3.483.130 32.33%
2013 -3.656.563 4.74%
2014 -5.628.000 35.03%
2015 -7.423.000 24.18%
2016 -6.072.000 -22.25%
2017 -7.375.000 17.67%
2018 -9.927.000 25.71%
2019 -12.678.000 21.7%
2020 -13.515.000 6.19%
2021 -15.093.000 10.46%
2022 -17.260.000 12.56%
2023 -18.148.000 4.89%
2023 -20.811.000 12.8%
2024 -5.124.000 -306.15%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

aXichem AB Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2008 0
2009 -1 0%
2010 -1 0%
2011 0 0%
2012 -1 100%
2013 -1 0%
2014 -1 0%
2015 -1 0%
2016 -1 0%
2017 -1 0%
2018 -1 0%
2019 -1 0%
2020 -1 0%
2021 -1 0%
2022 -1 100%
2023 -1 0%
2023 -1 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

aXichem AB Free Cashflow
Year Free Cashflow Growth
2008 -4.873.249
2009 -3.450.348 -41.24%
2010 -1.733.493 -99.04%
2011 -812.797 -113.28%
2012 -5.863.935 86.14%
2013 -6.148.384 4.63%
2014 -11.779.000 47.8%
2015 -12.367.000 4.75%
2016 -10.616.000 -16.49%
2017 -10.932.000 2.89%
2018 -11.136.000 1.83%
2019 -16.116.000 30.9%
2020 -18.928.000 14.86%
2021 -20.323.000 6.86%
2022 -21.706.000 6.37%
2023 -2.787.000 -678.83%
2023 -20.780.000 86.59%
2024 -4.869.000 -326.78%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

aXichem AB Operating Cashflow
Year Operating Cashflow Growth
2008 7.417.083
2009 -2.998.397 347.37%
2010 -1.131.528 -164.99%
2011 -428.503 -164.07%
2012 -4.885.777 91.23%
2013 -4.293.957 -13.78%
2014 -9.014.000 52.36%
2015 -7.977.000 -13%
2016 -5.526.000 -44.35%
2017 -7.688.000 28.12%
2018 -7.461.000 -3.04%
2019 -12.294.000 39.31%
2020 -11.694.000 -5.13%
2021 -15.595.000 25.01%
2022 -19.098.000 18.34%
2023 -2.787.000 -585.25%
2023 -15.677.000 82.22%
2024 -4.869.000 -221.98%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

aXichem AB Capital Expenditure
Year Capital Expenditure Growth
2008 12.290.332
2009 451.951 -2619.39%
2010 601.965 24.92%
2011 384.294 -56.64%
2012 978.158 60.71%
2013 1.854.427 47.25%
2014 2.765.000 32.93%
2015 4.390.000 37.02%
2016 5.090.000 13.75%
2017 3.244.000 -56.91%
2018 3.675.000 11.73%
2019 3.822.000 3.85%
2020 7.234.000 47.17%
2021 4.728.000 -53%
2022 2.608.000 -81.29%
2023 0 0%
2023 5.103.000 100%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

aXichem AB Equity
Year Equity Growth
2008 7.368.618
2009 5.649.099 -30.44%
2010 3.275.199 -72.48%
2011 9.129.823 64.13%
2012 8.012.725 -13.94%
2013 24.919.848 67.85%
2014 18.934.000 -31.61%
2015 26.270.000 27.93%
2016 41.331.000 36.44%
2017 33.861.000 -22.06%
2018 29.098.000 -16.37%
2019 67.154.000 56.67%
2020 53.650.000 -25.17%
2021 56.299.000 4.71%
2022 40.327.000 -39.61%
2023 48.527.000 16.9%
2023 54.506.000 10.97%
2024 64.641.000 15.68%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

aXichem AB Assets
Year Assets Growth
2008 15.865.108
2009 13.269.797 -19.56%
2010 14.738.481 9.96%
2011 22.508.465 34.52%
2012 17.357.362 -29.68%
2013 39.125.722 55.64%
2014 25.375.000 -54.19%
2015 30.874.000 17.81%
2016 47.010.000 34.32%
2017 38.561.000 -21.91%
2018 38.440.000 -0.31%
2019 68.973.000 44.27%
2020 55.748.000 -23.72%
2021 58.773.000 5.15%
2022 61.251.000 4.05%
2023 61.490.000 0.39%
2023 67.417.000 8.79%
2024 73.152.000 7.84%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

aXichem AB Liabilities
Year Liabilities Growth
2008 8.496.490
2009 7.620.698 -11.49%
2010 11.463.282 33.52%
2011 13.378.642 14.32%
2012 9.344.637 -43.17%
2013 14.205.874 34.22%
2014 6.441.000 -120.55%
2015 4.604.000 -39.9%
2016 5.679.000 18.93%
2017 4.700.000 -20.83%
2018 9.342.000 49.69%
2019 1.819.000 -413.58%
2020 2.098.000 13.3%
2021 2.474.000 15.2%
2022 20.924.000 88.18%
2023 12.963.000 -61.41%
2023 12.911.000 -0.4%
2024 8.511.000 -51.7%

aXichem AB Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.18
Net Income per Share
-0.41
Price to Earning Ratio
-2.9x
Price To Sales Ratio
7.13x
POCF Ratio
-3.56
PFCF Ratio
-3.62
Price to Book Ratio
0.75
EV to Sales
6.43
EV Over EBITDA
-7.78
EV to Operating CashFlow
-3.42
EV to FreeCashFlow
-3.26
Earnings Yield
-0.34
FreeCashFlow Yield
-0.28
Market Cap
0,05 Bil.
Enterprise Value
0,05 Bil.
Graham Number
3.86
Graham NetNet
0.32

Income Statement Metrics

Net Income per Share
-0.41
Income Quality
0.82
ROE
-0.29
Return On Assets
-0.23
Return On Capital Employed
-0.16
Net Income per EBT
1
EBT Per Ebit
1.66
Ebit per Revenue
-1.39
Effective Tax Rate
-0.32

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.22
Stock Based Compensation to Revenue
0
Gross Profit Margin
-0.71
Operating Profit Margin
-1.39
Pretax Profit Margin
-2.3
Net Profit Margin
-2.3

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.34
Free CashFlow per Share
-0.35
Capex to Operating CashFlow
-0.05
Capex to Revenue
0.09
Capex to Depreciation
0.17
Return on Invested Capital
-0.19
Return on Tangible Assets
-0.59
Days Sales Outstanding
462.89
Days Payables Outstanding
104.5
Days of Inventory on Hand
263.46
Receivables Turnover
0.79
Payables Turnover
3.49
Inventory Turnover
1.39
Capex per Share
0.02

Balance Sheet

Cash per Share
0,25
Book Value per Share
1,60
Tangible Book Value per Share
0.49
Shareholders Equity per Share
1.6
Interest Debt per Share
0.19
Debt to Equity
0.08
Debt to Assets
0.07
Net Debt to EBITDA
0.85
Current Ratio
3.3
Tangible Asset Value
0,02 Bil.
Net Current Asset Value
0,02 Bil.
Invested Capital
64641000
Working Capital
0,02 Bil.
Intangibles to Total Assets
0.62
Average Receivables
0,02 Bil.
Average Payables
0,00 Bil.
Average Inventory
8831000
Debt to Market Cap
0.1

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

aXichem AB Dividends
Year Dividends Growth

aXichem AB Profile

About aXichem AB

aXichem AB, a biotechnology company, engages in the development of natural analogue ingredients in Sweden. It offers aXivite, an natural analogue capsaicin solution for a range of dietary health applications; aXiphen-bio, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings and underground cables; and aXiphen-feed, a solution for enhanced health for chickens, hens, pigs, and piglets. The company was incorporated in 2007 and is based in Malmö, Sweden.

CEO
Mr. Torsten Helsing
Employee
7
Address
Södergatan 26
Malmö, 211 34

aXichem AB Executives & BODs

aXichem AB Executives & BODs
# Name Age
1 Ms. Gunilla Savring
Chief Investor Relations Officer
70
2 Mr. Torsten Helsing
Chief Executive Officer & Director
70
3 Mr. Erik Lager
Chief Technical Officer
70
4 Mr. Lucas Altepost
Vice President and Chief Sales & Marketing officer
70

aXichem AB Competitors

Enzymatica AB (publ) Logo
Enzymatica AB (publ)

ENZY.ST

(0.5)
Bactiguard Holding AB (publ) Logo
Bactiguard Holding AB (publ)

BACTI-B.ST

(0.2)
Cantargia AB (publ) Logo
Cantargia AB (publ)

CANTA.ST

(1.5)
BIMobject AB Logo
BIMobject AB

BIM.ST

(1.5)
Alzinova AB (publ) Logo
Alzinova AB (publ)

ALZ.ST

(1.5)